Lifewatch Services Inc v. Highmark Inc
902 F.3d 323
3rd Cir.2018Background
- LifeWatch, a seller of telemetry cardiac monitors, sued the Blue Cross Blue Shield Association and five member Blue Plans under Section 1 of the Sherman Act, alleging a decade-long, concerted refusal to reimburse telemetry monitors as "not medically necessary" or "investigational."
- Telemetry monitors record up to 30 days and automatically transmit data; other outpatient monitors (Holter, event, insertable) differ in cost, data capture, and ease of use. Some studies and independent review boards found telemetry medically necessary or superior in many cases.
- The Association maintains a national model medical policy (developed with Plan participation) recommending non-coverage of telemetry; most Blue Plans allegedly adopt that policy in near-uniform language.
- LifeWatch alleges the Association enforces “substantial compliance” with the model policy (the "Uniformity Rule") via audits and pressure (example: Highmark initially covered telemetry but later curtailed payments for non-subscribers).
- The District Court dismissed for failure to allege anticompetitive effects; the Third Circuit reversed, finding LifeWatch plausibly alleged agreement, market definition (national outpatient cardiac monitors as a buyer-side market), and anticompetitive effects, while leaving McCarran-Ferguson immunity for remand.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Existence of an agreement under §1 | Blue Plans and Association agreed (Uniformity Rule) to follow and enforce model policy denying telemetry coverage; meetings, audits, and pressure (Highmark) are circumstantial evidence | Plans independently and permissibly adopted model policy recommendations; no meeting of minds — parallel but independent conduct | Reversed: Complaint plausibly alleged parallel conduct plus "something more" (panel process, enforcement, specific pressure on Highmark) to survive Rule 12(b)(6) for agreement |
| Relevant product/market definition | National market for purchase of outpatient cardiac monitors (telemetry, Holter, event, insertable) viewed from sellers' perspective (buyer-side market of insurers) | Telemetry is distinct and not interchangeable with other monitors; product-market limited to telemetry only | Rejected District Court’s implicit telemetry-only market; Complaint plausibly pleaded nationwide outpatient cardiac monitor market (buyer-side focus on insurers) |
| Unreasonable restraint / anticompetitive effects | Concerted refusal to cover telemetry shifted demand to lower-quality substitutes, reduced output/innovation, deterred physician prescribing—actual competitive harms in the alleged market | Treating all telemetry sellers equally means no competition-reducing conduct; at most lawful buyer monopsony/independent cost-saving decisions | Reversed: Allegations of reduced demand, quality, and output in the outpatient cardiac monitor market suffice at pleadings stage to allege unreasonable restraint under rule-of-reason analysis |
| Antitrust standing and McCarran‑Ferguson immunity | LifeWatch (seller) suffered antitrust injury traceable to the conspiracy (lost profits; injury is the means defendants used to achieve anticompetitive ends) | Intervening factors (physician choices, independent Plan decisions) break causation; McCarran‑Ferguson may shield insurance conduct | Court held LifeWatch has antitrust standing (antitrust injury adequately pled). McCarran‑Ferguson immunity not decided on appeal; remanded for District Court to address it |
Key Cases Cited
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (plausibility standard for pleading conspiracy; parallel conduct plus "something more")
- In re Ins. Brokerage Antitrust Litig., 618 F.3d 300 (3d Cir. 2010) (circumstantial proof of agreement: parallel conduct plus plus-factors)
- W. Penn Allegheny Health Sys., Inc. v. UPMC, 627 F.3d 85 (3d Cir. 2010) (heightened scrutiny for buyer-side/oligopsony conduct; concerted activity risks)
- Am. Express Co. v. Italian Colors Restaurant, 138 S. Ct. 2274 (rule-of-reason framework requires market definition and proof of anticompetitive effects or market power)
- McCready v. Blue Shield of Va., 457 U.S. 465 (refusal-to-reimburse scheme can produce a "Hobson’s choice" and cause antitrust injury for excluded providers)
- Copperweld Corp. v. Indep. Tube Corp., 467 U.S. 752 (antitrust analysis of concerted vs. unilateral conduct)